Kalaris Therapeutics Inc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $63.3M
- Price
- $2.66
- % Change (Daily % change from the live per-ticker quote feed.)
- -6.01%
- Volume
- 103.4K
About
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Quick stats
Shares outstanding23.8M
Computed float5.6M
Float / shares23.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001754068
Websitehttps://kalaristx.com
AI Summary
AI-generated1/13
minorneutralother
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Kalaris Therapeutics announced that management will participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference.
CEO Andrew Oxtoby and CMO Matthew Feinsod are scheduled to speak on Tuesday, September 15, 2026, from 4:05 to 4:40pm EDT.
The company is developing TH103, a dual-action anti-VEGF therapeutic, currently in a Phase 1b/2 study for neovascular Age-related Macular Degeneration.